Glucocorticoid insensitive asthma: a one year clinical follow up pilot study. 1998

P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
INSERM U454, Hôpital Arnaud de Villeneuve, CHU de Montpellier, France.

BACKGROUND Glucocorticoid resistant or insensitive asthmatic subjects are usually defined as patients whose baseline pre-bronchodilation forced expiratory volume in one second (FEV1) of less than 70-80% predicted improves significantly in response to beta 2 agonists but by less than 15% following 1-2 weeks of 40 mg prednisolone daily. Since there is little long term clinical information on these patients, a one year prospective study was performed to assess whether glucocorticoid sensitivity may vary over time. METHODS Nineteen severe asthmatic subjects were studied and received 40 mg prednisolone daily for seven days. Prednisolone was given for a further seven days in glucocorticoid insensitive asthmatics and then stopped. Patients were followed up for one year and the glucocorticoid test was repeated on five patients in each group six months later. RESULTS Eleven patients were classified as glucocorticoid insensitive and eight as glucocorticoid sensitive on day 7. The demographic characteristics of the patients were similar in both groups. Four glucocorticoid insensitive patients became responsive after one further week of prednisolone treatment. Six months later, four of five glucocorticoid sensitive patients and three of five previously glucocorticoid insensitive patients were glucocorticoid sensitive. CONCLUSIONS Glucocorticoid sensitivity varies over time.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
December 2022, Diagnostics (Basel, Switzerland),
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
November 2007, Clinical research in cardiology : official journal of the German Cardiac Society,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
April 2020, Basic & clinical pharmacology & toxicology,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
September 2009, Journal of behavior therapy and experimental psychiatry,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
July 1969, Canadian family physician Medecin de famille canadien,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
January 1973, Scandinavian journal of thoracic and cardiovascular surgery,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
September 1976, NIDA research monograph,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
December 2002, Respiratory medicine,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
October 1961, Southern medical journal,
P Demoly, and D Jaffuel, and M Mathieu, and H Sahla, and P Godard, and F B Michel, and J Bousquet
December 1999, Wiener klinische Wochenschrift,
Copied contents to your clipboard!